Literature DB >> 17908703

Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia.

Ewoudt M W van de Garde1, Henrik Endeman, Vera H M Deneer, Douwe H Biesma, Fakhredin A Sayed-Tabatabaei, Henk J T Ruven, Hubert G M Leufkens, Jules M M van den Bosch.   

Abstract

BACKGROUND: Recent studies have suggested involvement of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism in the susceptibility to and severity of community-acquired pneumonia (CAP) in Asian populations. We have explored the hypothesis that the ACE I/D polymorphism affects the risk and outcome of CAP in a Dutch white population.
METHODS: This is a hospital-based prospective observational study including patients with CAP admitted between October 2004 and August 2006. All patients were genotyped, and pneumonia severity and clinical outcome were compared between patients with II, ID, and DD genotypes of the ACE gene. Pneumonia severity was assessed on day of hospital admission and consecutively on days 2, 3, 5, and 10 of hospital stay using the acute physiology score (APS). Outcomes evaluated were duration of hospital stay, ICU admittance, and in-hospital and 28-day mortality rates. To study the association between ACE genotype and risk of pneumonia, the distribution of the ACE I/D polymorphism was compared with healthy control subjects from the same geographic region.
RESULTS: In total, 200 patients with pneumonia and 200 control subjects were included in the study. Mean age of the patients was 63 years. APS scores were not different between the genotype groups on any of the days, and all clinical outcomes (duration of hospital stay, ICU admittance, in-hospital and 28-day mortality rates) were comparable between the three genotype groups. The ACE I/D genotype distribution was identical for patients and control subjects (p = 0.973).
CONCLUSIONS: The ACE I/D polymorphism is not associated with risk and outcome of CAP in the Dutch white population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908703     DOI: 10.1378/chest.07-1400

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Sources of heterogeneity in case-control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia.

Authors:  Mark C H de Groot; Olaf H Klungel; Hubert G M Leufkens; Liset van Dijk; Diederick E Grobbee; Ewoudt M W van de Garde
Journal:  Eur J Epidemiol       Date:  2014-08-26       Impact factor: 8.082

2.  Increased risk of pneumonia associated with angiotensin-converting enzyme (CD143) rs4340 polymorphism.

Authors:  Xiaofang Zhang; Fangzhu Liu
Journal:  Clin Exp Med       Date:  2015-05-16       Impact factor: 3.984

3.  CYP1A1, GCLC, AGT, AGTR1 gene-gene interactions in community-acquired pneumonia pulmonary complications.

Authors:  Lyubov E Salnikova; Tamara V Smelaya; Arkadiy M Golubev; Alexander V Rubanovich; Viktor V Moroz
Journal:  Mol Biol Rep       Date:  2013-09-26       Impact factor: 2.316

Review 4.  Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis.

Authors:  Daniel Caldeira; Joana Alarcão; António Vaz-Carneiro; João Costa
Journal:  BMJ       Date:  2012-07-11

5.  Association of the ACE, GSTM1, IL-6, NOS3, and CYP1A1 polymorphisms with susceptibility of mycoplasma pneumoniae pneumonia in Chinese children.

Authors:  Jie Zhao; Wen Zhang; Li Shen; Xiaomeng Yang; Yi Liu; Zhongtao Gai
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

6.  Angiotensin-converting enzyme polymorphism affects outcome of local Chinese with acute lung injury.

Authors:  Xiao-Min Lu; Guang-Jian Chen; Yi Yang; Hai-Bo Qiu
Journal:  Respir Med       Date:  2011-07-13       Impact factor: 3.415

Review 7.  Genetic Association Between CD143 rs4340 Polymorphism and Pneumonia risk: A Meta Analysis.

Authors:  Hong Wang; Kun Zhang; Haifeng Qin; Lin Yang; Liyu Zhang; Yanyan Cao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.